See more : EssilorLuxottica Société anonyme (EL.PA) Income Statement Analysis – Financial Results
Complete financial analysis of CareDx, Inc (CDNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CareDx, Inc, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- BlackRock, Inc. (BLQA.DE) Income Statement Analysis – Financial Results
- Choksi Imaging Limited (CHOKSI.BO) Income Statement Analysis – Financial Results
- EQB Inc. (EQB.TO) Income Statement Analysis – Financial Results
- Dürr Aktiengesellschaft (DURYY) Income Statement Analysis – Financial Results
- Tree Island Steel Ltd. (TWIRF) Income Statement Analysis – Financial Results
CareDx, Inc (CDNA)
About CareDx, Inc
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 280.32M | 321.79M | 296.40M | 192.19M | 127.07M | 76.57M | 48.32M | 40.63M | 28.14M | 27.31M | 22.10M | 20.45M |
| Cost of Revenue | 102.00M | 112.21M | 97.39M | 63.12M | 45.46M | 32.99M | 21.37M | 21.12M | 10.27M | 8.54M | 9.08M | 7.93M |
| Gross Profit | 178.33M | 209.58M | 199.01M | 129.08M | 81.61M | 43.58M | 26.95M | 19.51M | 17.87M | 18.77M | 13.02M | 12.52M |
| Gross Profit Ratio | 63.61% | 65.13% | 67.14% | 67.16% | 64.23% | 56.92% | 55.78% | 48.02% | 63.50% | 68.72% | 58.92% | 61.22% |
| Research & Development | 81.87M | 90.39M | 76.53M | 48.94M | 30.71M | 14.51M | 12.39M | 12.39M | 9.33M | 3.85M | 3.18M | 4.75M |
| General & Administrative | 117.87M | 100.40M | 74.96M | 48.81M | 36.54M | 21.96M | 18.91M | 20.73M | 12.25M | 8.44M | 4.81M | 4.69M |
| Selling & Marketing | 83.33M | 96.03M | 77.25M | 53.86M | 38.89M | 21.67M | 12.81M | 11.17M | 8.35M | 6.47M | 5.89M | 5.42M |
| SG&A | 201.20M | 196.42M | 152.21M | 102.66M | 75.43M | 43.63M | 31.72M | 31.89M | 20.60M | 14.91M | 10.70M | 10.11M |
| Other Expenses | 98.62M | -2.87M | -2.63M | -4.81M | -719.00K | -178.00K | -1.49M | -1.92M | -188.00K | 147.00K | -536.00K | -14.00K |
| Operating Expenses | 381.69M | 286.81M | 228.73M | 146.79M | 106.15M | 58.14M | 44.11M | 44.28M | 29.93M | 18.75M | 13.88M | 14.86M |
| Cost & Expenses | 483.69M | 399.02M | 326.12M | 209.91M | 151.60M | 91.13M | 65.48M | 65.40M | 40.20M | 27.30M | 22.96M | 22.79M |
| Interest Income | 11.87M | 3.76M | 160.00K | 271.00K | 985.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 3.76M | 0.00 | 271.00K | 0.00 | 3.70M | 5.86M | 1.86M | 1.59M | 2.12M | 2.15M | 2.70M |
| Depreciation & Amortization | 19.82M | 16.01M | 11.89M | 9.54M | 5.52M | 4.22M | 3.76M | 2.92M | 796.00K | 512.00K | 663.00K | 1.07M |
| EBITDA | -89.66M | -61.22M | -17.84M | -10.21M | -19.01M | -11.36M | -14.61M | -17.85M | -11.26M | 523.00K | -194.00K | -1.27M |
| EBITDA Ratio | -31.98% | -24.03% | -10.06% | -8.44% | -19.56% | -19.25% | -38.59% | -65.68% | -43.29% | -4.50% | -0.88% | -6.21% |
| Operating Income | -203.36M | -77.23M | -29.73M | -17.72M | -24.53M | -15.58M | -20.29M | -37.33M | -11.93M | 1.25M | -857.00K | -2.34M |
| Operating Income Ratio | -72.55% | -24.00% | -10.03% | -9.22% | -19.31% | -20.35% | -42.00% | -91.88% | -42.40% | 4.58% | -3.88% | -11.45% |
| Total Other Income/Expenses | 13.22M | 997.00K | -2.36M | 2.78M | 585.00K | -32.64M | -36.98M | -4.03M | -1.78M | -1.97M | -2.69M | -2.72M |
| Income Before Tax | -190.14M | -76.23M | -32.09M | -19.75M | -23.95M | -48.22M | -57.27M | -41.36M | -13.71M | -719.00K | -3.54M | -5.06M |
| Income Before Tax Ratio | -67.83% | -23.69% | -10.83% | -10.28% | -18.85% | -62.97% | -118.51% | -101.80% | -48.70% | -2.63% | -16.03% | -24.74% |
| Income Tax Expense | 141.00K | 379.00K | -1.43M | -1.04M | -1.98M | -1.43M | -1.71M | -1.61M | 665.00K | -1.50M | 2.15M | 2.70M |
| Net Income | -190.28M | -76.61M | -30.66M | -18.71M | -21.97M | -46.76M | -55.47M | -39.47M | -13.71M | 781.00K | -3.54M | -5.06M |
| Net Income Ratio | -67.88% | -23.81% | -10.34% | -9.74% | -17.29% | -61.06% | -114.79% | -97.14% | -48.70% | 2.86% | -16.03% | -24.74% |
| EPS | -3.54 | -1.44 | -0.59 | -0.40 | -0.52 | -1.31 | -2.38 | -2.39 | -1.16 | 0.13 | -0.48 | -0.69 |
| EPS Diluted | -3.54 | -1.44 | -0.59 | -0.40 | -0.52 | -1.31 | -2.38 | -2.39 | -1.16 | 0.10 | -0.48 | -0.69 |
| Weighted Avg Shares Out | 53.76M | 53.32M | 52.24M | 46.48M | 42.15M | 35.64M | 23.31M | 16.50M | 11.82M | 5.82M | 7.37M | 7.37M |
| Weighted Avg Shares Out (Dil) | 53.76M | 53.32M | 52.24M | 46.48M | 42.15M | 35.64M | 23.33M | 16.50M | 11.86M | 9.28M | 7.37M | 7.37M |
CareDx Adds to AlloSure Kidney and HeartCare Utility and Clinical Data at 2024 American Society of Transplant Surgeons Winter Symposium
CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2023
CareDx Joins Forces with the National Foundation for Transplants to Improve Post-Transplant Medication Adherence
How Much Upside is Left in CareDx (CDNA)? Wall Street Analysts Think 26.72%
Can CareDx (CDNA) Climb 29.79% to Reach the Level Wall Street Analysts Expect?
CareDx, Inc (CDNA) Q3 2023 Earnings Call Transcript
CareDx Reports Third Quarter 2023 Results
CareDx (CDNA) Surges 16.6%: Is This an Indication of Further Gains?
CareDx Announces CEO Transition
CareDx Presents New Data at the American Society for Histocompatibility and Immunogenetics Annual Meeting
Source: https://incomestatements.info
Category: Stock Reports